SG11202005983TA - Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors - Google Patents

Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors

Info

Publication number
SG11202005983TA
SG11202005983TA SG11202005983TA SG11202005983TA SG11202005983TA SG 11202005983T A SG11202005983T A SG 11202005983TA SG 11202005983T A SG11202005983T A SG 11202005983TA SG 11202005983T A SG11202005983T A SG 11202005983TA SG 11202005983T A SG11202005983T A SG 11202005983TA
Authority
SG
Singapore
Prior art keywords
mertk
tyro3
axl
tam
family
Prior art date
Application number
SG11202005983TA
Inventor
Shih-Chieh Yen
Chu-Bin Liao
Hui-Chen Wang
Po-Ting Chen
Yu-Chih Pan
Tsung-Hui Li
bo-rong Chen
Shian-Yi Chiou
Original Assignee
Dev Ct Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dev Ct Biotechnology filed Critical Dev Ct Biotechnology
Publication of SG11202005983TA publication Critical patent/SG11202005983TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SG11202005983TA 2017-12-28 2018-12-26 Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors SG11202005983TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762610994P 2017-12-28 2017-12-28
PCT/US2018/067532 WO2019133629A1 (en) 2017-12-28 2018-12-26 Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11202005983TA true SG11202005983TA (en) 2020-07-29

Family

ID=67068139

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005983TA SG11202005983TA (en) 2017-12-28 2018-12-26 Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors

Country Status (10)

Country Link
US (1) US11407757B2 (en)
EP (1) EP3731845A4 (en)
JP (1) JP2021510729A (en)
KR (1) KR20200104336A (en)
CN (1) CN112203659A (en)
AU (1) AU2018397483A1 (en)
CA (1) CA3086714A1 (en)
SG (1) SG11202005983TA (en)
TW (1) TWI691500B (en)
WO (1) WO2019133629A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023043836A1 (en) * 2021-09-15 2023-03-23 Metacrine, Inc. Hsd17b13 inhibitors and uses thereof
WO2023049270A1 (en) * 2021-09-24 2023-03-30 Halia Therapeutics, Inc. Pyrrole[2,3-b]pyridine derivatives as tyro3 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042299A1 (en) * 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
US7981903B2 (en) * 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
WO2009049028A1 (en) * 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
AU2010210986A1 (en) * 2009-02-09 2011-08-25 Supergen, Inc. Pyrrolopyrimidinyl Axl kinase inhibitors
ES2650630T3 (en) * 2011-10-03 2018-01-19 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for cancer treatment
SG11201505446WA (en) * 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
EP3169686A4 (en) * 2014-07-14 2018-01-24 Signal Pharmaceuticals, LLC Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CN105646496B (en) * 2016-01-20 2018-07-20 华侨大学 A kind of 7H- pyrrolo-es [2,3-d] pyrimidine derivatives, its synthetic method and application

Also Published As

Publication number Publication date
WO2019133629A8 (en) 2020-01-16
TW201930306A (en) 2019-08-01
JP2021510729A (en) 2021-04-30
TWI691500B (en) 2020-04-21
KR20200104336A (en) 2020-09-03
EP3731845A1 (en) 2020-11-04
EP3731845A4 (en) 2021-10-06
US11407757B2 (en) 2022-08-09
CN112203659A (en) 2021-01-08
AU2018397483A1 (en) 2020-08-13
US20210009597A1 (en) 2021-01-14
CA3086714A1 (en) 2019-07-04
WO2019133629A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
MX2017006366A (en) 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors.
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
CL2016002382A1 (en) Quinoxaline derivatives useful as modulators of fgfr kinase
EP3310339A4 (en) Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
EP3672973A4 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
EA201591420A1 (en) Heteroaryl Compounds and Their Use
IL260263A (en) Use of tryptophan derivatives for protein formulations
IL282801A (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
EP3310776A4 (en) Inhibitors of bruton's tyrosine kinase
EA201790395A1 (en) AMINOTRIAZIN DERIVATIVES SUITABLE FOR USING AS TANK-BINDING KINASE INHIBITORS
EP3174539A4 (en) Inhibitors of bruton's tyrosine kinase
MX2016015565A (en) Certain protein kinase inhibitors.
IL250447A0 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
IL259863B (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
EP3448852A4 (en) Novel heterocyclic compounds as tyrosine kinase bcr-abl inhibitors
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
SG11202005983TA (en) Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
GB2579149B (en) Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient
WO2014193696A3 (en) Benzimidazole carboxylic acid derivatives, compositions, and methods of use as aurora kinase inhibitors
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors